Ahn IE et al. Clinically-indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood 2019;133(22):2452-5. Abstract
Burger JA et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019;133(10):1011-9. Abstract
ELEVATE CLL TN: A randomized, multicenter, open-label, 3 arm phase 3 study of obinutuzumab in combination with chlorambucil, acalabrutinib (ACP-196) in combination with obinutuzumab, and acalabrutinib monotherapy in subjects with previously untreated CLL. NCT02475681
Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract
Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc EHA 2019;Abstract LB2606.
Goede V et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: Final survival analysis of the CLL11 study. Proc EHA 2018;Abstract S151.
Jain N et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019;380(22):2095-103. Abstract
Janus A, Robak T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin Biol Ther 2019;19(6):501-8. Abstract
Kater AP et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37(4):269-77. Abstract
Mato AR et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv 2019;3(10):1568-73. Abstract
Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract
Roeker LE et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res 2019;25(14):4264-70. Abstract
Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107-20. Abstract
Shanafelt TD et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). Proc ASH 2018;Abstract LBA-4.
Siddiqi T et al. TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Proc ASCO 2019;Abstract 7501.
Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019;133(12):1298-307. Abstract
Stilgenbauer S et al. Venetoclax for patients with CLL with 17p deletion: Results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36(19):1973-80. Abstract
Turtle CJ et al. Durable molecular remissions in CLL treated with CD19-specific chimeric antigen receptor (CAR)-modified T cells after failure of ibrutinib. J Clin Oncol 2017;35(26):3010-20. Abstract
Woyach J et al. Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up. Proc ASCO 2019;Abstract 7500.
Woyach JA et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Proc ASH 2018;Abstract 6.
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract